NCT07046611View on ClinicalTrials.gov

Ketamine and Levetiracetam as Second-line Antiseizure Medication for Status Epilepticus in Children

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

July 2, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

July 1, 2026

Conditions
Generalized Convulsive Status Epilepticus
Interventions
DRUG

Ketamine

Intravenous ketamine (5 mg/ml concentration) 2 mg/kg (max 90 mg) over 2 minutes

DRUG

Levetiracetam

Intravenous levetiracetam (50 mg/ml concentration) 60 mg/kg (max 4500 mg) over 5 minutes

DRUG

Placebo

Intravenous isotonic saline 0.4 mL/kg (maximum 18 mL) over 2 minutes

Trial Locations (1)

82524

RECRUITING

Department of Pediatrics at Sohag University Hospital, Sohag

All Listed Sponsors
lead

Sohag University

OTHER